r&d activities in dermatology kenneth watson md mba executive director beauty eurasia seminar...
Post on 19-Dec-2015
216 views
TRANSCRIPT
R&D Activities in DermatologyKenneth Watson MD MBA
Executive DirectorBeauty Eurasia Seminar
Istanbul, June 14 2007
Introduction
• Galderma : the world-leading company in dermatology
−Acne, Rosacea
−Psoriasis, Steroid-Responsive Dermatoses
−Skin Cancer, Pigmentation Disorders, Onychomycosis
−New : Aesthetic & Corrective Dermatology
• Focus on R&D and innovation
−Biggest investor in dermatological R&D (together with L’Oreal)
• Presentation focused on research, drug development and new products “from a business perspective”
Galderma’s Ambition
To be recognized as the most competent and successful
innovation-based company focused exclusively on
meeting the needs of dermatology patients
and physicians
The World of Modern Health CareDynamics in Obtaining & Providing Treatments
PROVIDERS
-Pharmaceutical (Rx / OTx)
-Cosmetic (OTC)
-Procedures
PATIENTS
‘SENIOR’ CUSTOMERS
TREATERS- Derms- GPs/PCPs- Pharmacists- Beauty Spa centres
SOLUTIONS
PAYERS
Health Care & Managed Care
Beauty centreInternet -telemedicineAbility to pay
-Rx: R&D cost
-Procedures: Physicians
Evidence-based medicine
Income-related practise
Cost containment“Need-clause”
Power of patients grows worldwide
Changing Environment for Dermatologists
Trends impacting Dermatology
Source: Galderma Business Intelligence Reports
Competitive environment for
Pharmaceutical companies:- Dermatology is still an
“open market”-Low barrier of entry, many
new competitors
Epidemiology trends:- Aging population
- Cases of skin cancer will increase
Evolution of Health Care systems:
- Pressure on healthcare costs- De-reimbursement from public to
private or patient-cash outlay - Generics
Evolution of how Dermatology conditions
are treated:-Dermatologists will
focus on moderate to severe conditions and conditions treated
by procedures- GP as Gatekeeper
Efficiency : Critical aspect of drug development
“New Drugs” in Clinical Studies (1995 – 2004)
0
250
500
750
1000
1250
1500
Phase I Phase II Phase III
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
Drugs in clinical trials from 1995-2004
Nu
mbe
r of
dru
gs
Source: Pharmaprojects 2004
5 6215 507
3 5673 233
1 3211 576
1977-80 1981-84 1985-88 1990-92 1994-95 1998-01
Approval Period
Su
bje
cts
Mean Number of Subjects in NDAs
Sources: Boston Consulting Group, 1993; Peck, Food and Drug Law J, 1997; PAREXEL, 2002
5,9
8,8
8,6
9,4
9,3
10,4
1,4
2,3
1,8
2
2,1
1,4
2,6
3,8
2,9
2,9
4,4
5
0 4 8 12 16 20
Anti-infective
Cardiovascular
All
Analgesic/Anesthetic
CNS
Antineoplastic
Years
Synthesis to 1st in Humans 1st in Humans to NDA Approval Phase
16.2
14.3
14.3
14.2
13.7
12.3
Mean Development & Approval Times
Source: DiMasi, Clin Pharmacol Ther, 2001;69(5):286-96
FDA NME Approvals
Source : www.fda.gov
Development Costs per Approved Drug
121
336 282
466403
802
0100200300400500600700800900
Mil
lio
ns
of
"20
00
$"
Preclinical Clinical Total
Out-of-Pocket Capitalized
Source: DiMasi et al., J Health Economics 2003;22(2):151-185
At 7% annual growth $1.5 billion by 2015
Observations
• Governments and Health Care Institutes face dramatically rising costs and aim at cost-containment
• Developing innovative products takes > 7 years, and is risky and very costly
−Many pharmaceutical companies struggle to launch good new products
• Dermatology: little innovation in past decades
−Aesthetic dermatology is “booming and blooming”
−Innovative R&D continues……
2004 Worldwide Dermatology Business27.7 billion US $
14.1 Billion US$ CAGR: +3,5 %
1.2 Billion US$ CAGR: +10 %
10.1 Billion US$ CAGR: +4 %
1 Billion US$ CAGR: +10 %
0.8 Billion US$ CAGR: +10 %
0.6 Billion US$ CAGR: +10 %
CAGR: 2004 - 2014
Innovation & GrowthDermatology “Disease” Areas
Innovation ("public")
Market growth
High
High
Low
Low
Acne
acne
Rosacea
rosacea
Pso/SRD
psoriasis/SRD
PD
PD
Onychomycosis
onychomycosis
skin cancers
SkinCancers
Innovation :# leads in development# launches 2002-2007
Market growth:% growth in $ (’02-’07)
aesthetic dermatology
AestheticDermatology
Doctor driven
Medical condition
Patient driven
Aesthetic condition
Acne
Melasma
PD/ PA
Photodamage/ Photoaging (AK)
Pigmentation disorders
Vitiligo
PIH
Psoriasis
Skin cancer
Solar Lentigo
Rosacea
Most treatments reimbursed
Most treatments not reimbursed
Becomes medical/reimbursed if cancer risk
Health Care Position on Reimbursements
•Causes unknown - Autoimmune disease
•Fewer treatments and less predictable response than Melasma
Acne Trends Strength & intensity of competition
Food, Drug, Mass
HealthBeauty
Cosmeceuticals*€1.8bn
Med
icat
ed O
TC
*$1
.6b
n
No
n-M
ed
icat
ed
OT
C*
2.0b
n€
Rx**
€2.2bn
Proactiv $400m Neutrogena $50m Clean & Clear $36m Clearasil $30mPhysiogel
Efflacar AIClearenceExfoliac
Soap Hand & Body Lotion Facial Cleansers Moisturizers
Navigant 2005* ; IMS MAT 2006**; Kine&Co report 2006*** Feedback research services 2006****
Medicated OTX***
Derms onlyUS $ 99m
+16.3% 02-05****
Acne: $20m Mostly cleanser
Total professional market (ageing, acne )*** Pharmacy, Dr, internet, Spa ww 1.65b€ +43% cagr 02-05
Pharmacy
Kinerase $22.3m +43% 04-05
SkinceuticalsNV PerriconeSkinmedica
Lasers
Dermabrasion
Peeling
OLS
Isotretinoin
Retinoids
Antibiotics
Dr Dispensed
Procedures
Spa
Cetaphil
Acne R&D
Galderma R&D
PPAR/RAR concepts
0
10
20
30
40
50
60
70
80
90
before2000
2000 2001 2002 2003 2004 2005 2006 2007
molecular
cellular
Pharmacology tests
RARVDR
PPARRXR
LXRPPAR PPAR
FP-RMC1-R
TYROSINASE
SOAT
TACERoDH4DHRS9
AR
Steroid receptors
(ER, GR, PR, MR)
HSD11b 1, 2
3HSDHyaluronidasesCollagénases
MMPADAM
NFKappa BTNF
CXCR1 CXCR2NRs GPCRs ENZYMES
INFLAMMATION PATHWAY
Patients
Getting older, living longer
Changing Life style
Cash out to enhance appearance
Easy access to Information
Young and old…….: beauty is what matters!
DermatologistsPlastic surgeons
Others …
Procedures
Skin preparation
Combination treatment : efficacy enhancement
Comfort improvementMaintenance treatment
Fillers BTX-A
Patient Management
• Skin Care• Anaesthetics• Keratolytics/ Peelings
• Skin Care/ Sun blocks• Wound healing• Retinoids
• Retinoids• Hydroquinone• Anti-inflammatory
PDT
• « Classic » indications:
− Nasolabial folds
− Mouth area: corners, vermilion border and body
− Marionette lines
• Volume indications:
− Cheeks, chin
− Scars
− Lipoatrophy
• “Advanced” indications (difficulty)
− Tear trough
− Glabellar and crow’s feet
− Ears and nose
− Brow
− Body indications: neck, hands
Dermal fillers: from « classic » to « advanced » indications
Galderma: focus on patient interest &comfort. New topical anesthetic!
Dosage and administration:• For minor procedures: 20-30 minutes • For major procedures: 60 minutes
How it works:• Improved transdermal delivery• Delivery stops once completely dry• Stays where it is placed and adheres to folds and contours on the face and other parts of the body • Formulation allows for easy removal of product
Main competitive advantages:• Greater efficacy• Mean duration: 11 hours• No occlusion• Easy removal
Evolution of Dermatology Practice ?
Past & Present Present & Future
Medicalindications
Procedures
Corrective & Aesthetic indications
Rx/non-Rxtopicals and systemics
Corrective & Aesthetic indications
Rx/non-Rxtopicals and systemics
Procedures
Medicalindications
Source: Internal Phase I reportDermatological Procedures: Preliminary evaluation and market opportunity- October 2005
Conclusions
• Dermatology: even more focus on patient needs (beauty-driven)
• Development of effective, innovative drugs is challenging & costly
• Procedures; important!
• Aesthetic & corrective dermatology revolutionizes dermatological practices
• R&D : no longer exclusively focused on new drugs
Istanbul :
a beautiful city!